Liminal BioSciences Inc.
DelistedCIK 1351172fmd_0HD47CJEY4W3AAJDG4T0QM4VMDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Jun 30, 2023, 11 periods
Latest annual · FY2022
Millions- Total revenues
- 0
- Net income
- 1
- Free cash flow
- (32)
Latest quarter · Q2 FY2023
Millions- Total revenues
- 0
- Net income
- (9)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2019 to FY2022
- -18.7%
- Revenue, 5 yearsFY2017 to FY2022
- -55.2%
- Net income, 5 yearsFY2017 to FY2022
- n/m
Liminal BioSciences Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Revenue | CA$401,000 | CA$643,000 | -37.6% | 20-F 2023-03-15 · proof |
| Net income | CA$622,000 | CA$12.2 million | -94.9% | 20-F 2023-03-15 · proof |
| Cash from operating activities | -CA$31.8 million | -CA$99.6 million | 20-F 2023-03-15 · proof | |
| Free cash flow | -CA$31.8 million | -CA$99.9 million | 20-F 2023-03-15 · proof | |
| Total assets | CA$50.5 million | CA$126.1 million | -60% | 20-F 2023-03-15 · proof |
| Total liabilities | CA$14.3 million | CA$92.2 million | -84.5% | 20-F 2023-03-15 · proof |
| Cash and cash equivalents | CA$37.1 million | CA$108.5 million | -65.8% | 20-F 2023-03-15 · proof |
| Total debt | CA$0 | CA$38.3 million | -100% | 20-F 2023-03-15 · proof |
- What was Liminal BioSciences Inc.'s revenue in fiscal 2022?
- Liminal BioSciences Inc. reported revenue of CA$401,000 for fiscal 2022 (the year ended Dec 31, 2022), against CA$643,000 the year before (-37.6%). Source: the 20-F filed with the SEC on Mar 15, 2023. SEC
- What was Liminal BioSciences Inc.'s net income in fiscal 2022?
- Liminal BioSciences Inc. reported net income of CA$622,000 for fiscal 2022 (the year ended Dec 31, 2022), against CA$12.2 million the year before (-94.9%). Source: the 20-F filed with the SEC on Mar 15, 2023. SEC
- What was Liminal BioSciences Inc.'s cash from operating activities in fiscal 2022?
- Liminal BioSciences Inc. reported cash from operating activities of -CA$31.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -CA$99.6 million the year before. Source: the 20-F filed with the SEC on Mar 15, 2023. SEC
- What was Liminal BioSciences Inc.'s free cash flow in fiscal 2022?
- Liminal BioSciences Inc. reported free cash flow of -CA$31.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -CA$99.9 million the year before. Source: the 20-F filed with the SEC on Mar 15, 2023. SEC
- What are Liminal BioSciences Inc.'s total assets?
- As of Dec 31, 2022, Liminal BioSciences Inc. reported total assets of CA$50.5 million, against CA$126.1 million a year earlier (-60%). Source: the 20-F filed with the SEC on Mar 15, 2023. SEC
- What are Liminal BioSciences Inc.'s total liabilities?
- As of Dec 31, 2022, Liminal BioSciences Inc. reported total liabilities of CA$14.3 million, against CA$92.2 million a year earlier (-84.5%). Source: the 20-F filed with the SEC on Mar 15, 2023. SEC
- What are Liminal BioSciences Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, Liminal BioSciences Inc. reported cash and cash equivalents of CA$37.1 million, against CA$108.5 million a year earlier (-65.8%). Source: the 20-F filed with the SEC on Mar 15, 2023. SEC
- What is Liminal BioSciences Inc.'s total debt?
- As of Dec 31, 2022, Liminal BioSciences Inc. reported total debt of CA$0, against CA$38.3 million a year earlier (-100%). Source: the 20-F filed with the SEC on Mar 15, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1351172&period_type=annual&limit=5"Information only, not investment advice.